- November 13, 2016: Charles-Louis d’Orléans is once again running the marathon of Athens for DGMRF. Thank you my friend for your continuous and renewed support to this cause!
- November 6, 2016: Lorenzo Lorenzotti today ran the New York City marathon on behalf of the de Gunzburg Myeloma Research Foundation.
Thank you Lorenzo for proving us your continued support to our cause to fight myeloma, the last totally incurable form of cancer.
Your everlasting friendship and care not only helps us towards a cure but inspires us every day in our battle: We need it!
- May 7, 2016: Sophie Smith is running the half-marathon of Bridgehampton again on behalf of DGMRF. Thank you Sophie for your eternal support. We hope all myeloma patients could enjoy as much perseverance in the long run like your dedication to the cause.
- April 30, 2016: Interview of Mr. Vivien de Gunzburg by Dr. Paul Richardson, Myeloma Center, Dana-Farber Cancer Institute (Harvard) during The 2nd World Congress on Controversies in Multiple Myeloma taking place in Paris.
- April 24, 2016: Guillaume Houze is running the marathon of London for DGMRF. Thank you old brother for your help for this new cause you decided to support!
- January 2016: DGMRF was directly involved in the development of Daratumumab and Panobinostat, or 2 out of 4 drugs (50%) that made it to the market in 2015 THANKS TO THE EXPERIENCE WITH « IDS » AND RESEARCH OF DR CONSTANTINE MITSIADES AND HIS LABORATORY AT DFCI. In addition, the DFCI clinical team led by Dr. Paul Richardson that DGMRF supports was involved in all 4 drugs that came to the market. This highlights that with a relatively new and small foundation, DGMRF contributed to making real changes in the field of myeloma thanks to the team it selected to fully support.
- December 2015: Lorenzo Lorenzotti runs the marathon of New York, and Charles-Louis d’Orleans runs the marathon of Athens on behalf of the de Gunzburg Myeloma Research Foundation.
- December 2015: Dr Richardson and Dr Mitsiades from DFCI present their findings at ASH, including 2 drugs dedicated to myeloma that made it to the market in 2015 partially developned by DGMRF.
- May 9, 2015: Sophie Smith, Ellen Benveniste and Liz Alber once again run the Bridghampton Half Marathon on behalf of DGMRF.
- February 2015: Approval by the US Food and Drug Administration (FDA) of Panobinostat for the treatment of relapsed/refractory MM.Panobinostat, which falls within a category of drugs called HDAC inhibitors, is the first of its kind to receive FDA approval for clinical use in MM patients—providing a new therapeutic option for patients who no longer respond to standard treatment. Nearly a decade ago, Dr. Mitsiades’ preclinical studies first demonstrated that broad-spectrum anti-HDAC drugs can augment the response of myeloma cells to proteasome inhibitors (such as Bortezomib) or to immunomodulatory Thalidomide derivatives. The pivotal randomized phase III clinical trial PANORAMA 1, combining the broad-spectrum HDAC inhibitor Panobinostat with Bortezomib, validated Dr. Mitsiades’ work. Dr. Richardson was senior investigator on the Panobinostat trial, which provided the basis for the drug’s FDA approval.
- December 6-9, 2014: Developments of the DGMRF’s program realized by Dr Paul Richardson and Dr Constantine Mitsiades at the Dana Farber Cancer Institute in Boston will be presented at the American Society of Hematology’s annual meeting in San Franciso.
(Please see document 1 herewith) (Please see document 2 herewith)
(Please see document 3 herewith) (Please see document 4 herewith)
- December 2, 2014: DGMRF participates to Giving Tuesday. Sandell Asset Management matches every donation made to DGMRF on Giving Tuesday! Participate as well. Support early stage research for myeloma at « Deductible donation page ».
- November 2, 2014: Nicolas Macquin and other friends ran and finished the New York City Marathon on behalf of myeloma and DGMRF.
- July 2014: Dr Paul Richardson and Dr Constantine Mitsiades, running DGMRF’s program at the Dana Farber Cancer Institute, are named two of the « Most Influential Scientific Minds » of 2014 by Thomson Reuters. (Please see article herewith).
- May 10, 2014: Half marathon run on May 10th in Bridgehampton, New York, by Sophie Smith and her friends Sonia Porter, Ellen Benveniste, and Liz Alber on behalf of DGMRF.
- December 2013: DFCI renders the first results of its research to DGMRF.
- August 2012: The de Gunzburg Myeloma Research Foundation received its official tax exempt status from the Internal Revenue Service (Department of the Treasury) retroactively to the date of its creation. DGMRF is hence exempt from Federal income tax income under section 501(c)(3) of the Internal Revenue Code.
- June 2012: Dana-Farber Cancer Institute (« DFCI ») applied for a research grant to the de Gunzburg Myeloma Research Foundation.
The de Gunzburg Myeloma Research Foundation accepted this first research grant, and has committed to a five year fundamental research program led by Paul Richardson MD and Constantines Mitsiades MD, PhD within the myeloma effort of the Dana-Farber Cancer Institute (Harvard) in Boston (MA, USA).
- May 2012: The de Gunzburg Myeloma Research Foundation is capitalized, and starts accepting donations as well as analyzing potential myeloma research grants from hospitals and laboratories. DGMRF also applies for tax-exempt status.
- March 2012: The de Gunzburg Myeloma Research Foundation is officially incorporated in the US as a private foundation.
The de Gunzburg Myeloma Research Foundation (“DGMRF”) was established to finance research programs from and within third parties’ leading medical institutions. The DGMRF is a non-profit private foundation which has tax exempt status under section 501(c)(3) of the United States of Americas’ Internal Revenue Code.
Any information and/or data available on the website of the DGMRF (the “Website”) is accessible to anybody. This Website does not purport to contain all the information (the “Information”) to understand and/or evaluate all of the factors regarding myeloma. Any reader hereof should conduct his/her own investigation and analysis on the disease, including as the case may be, based on the specificities relating to the potential myeloma patient.
The DGMRF has not independently verified the Information contained on the Website. The DGMRF makes no representation or warranty of any kind, express or implied, as to the accuracy or completeness of the Information or any other written or oral communication transmitted or made available. The DGMRF and their representatives hereby expressly disclaim any and all liability based, in whole or in part, on such Information, including without limitation regarding (a) the quality, accuracy, timeliness, or completeness of the Information, and (b) fitness for a particular purpose. In no event shall DGMRF be liable for any direct or indirect, incidental, exemplary, special, punitive, or consequential damages relating to the use of this Information.